Cushing’s Syndrome – Opportunity Assessment and Forecast to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

GlobalData estimates that 2020 sales for Cushing’s syndrome (CS) therapies were approximately $121.4 million, with the US and Germany dominating the market. The sales are expected to grow at a CAGR of more than 10% during 2020-2030. GlobalData expects the number of diagnosed prevalent cases of Cushing’s syndrome (CS) to be 25,625 cases in 2020, increasing at a negligible Annual Growth Rate (AGR) of less than 1% across the two major markets.

In 2020, the US had the highest number of diagnosed prevalent cases of CS (endogenous), followed by Germany. There are currently two therapies in the late-stage pipeline: Recorlev (levoketoconazole), which is in pre-registration in the US, and Relacorilant which is in Phase III in the EU and US.

Cushing’s Syndrome Market Overview

Global Cushing’s Syndrome market overview

For more insights on this report, download a free report sample

What are the treatment options available for Cushing’s syndrome?

In patients with overt CS, the treatment recommendation is to normalize cortisol levels or alter the response of cortisol receptors to eliminate the signs and symptoms of CS. Treatments designed to normalize cortisol or its action, are not recommended when there is only a borderline abnormality in the hypothalamic-pituitary-adrenal (HPA) axis without any specific signs of CS. Unilateral resection should be carried out in all cases of benign unilateral disease. ACTH-secreting tumors need to be localized and resected with node dissection. Transsphenoidal selective (TSS) adenectomy is the optimal treatment for CD in pediatric and adult patients.

Some of the essential molecules or drugs recommended for the treatment of CS include Korlym (mifepristone), Isturisa (osilodrostat phosphate), Signifor (pasireotide), Signifor LAR (pasireotide), Ketoconazole (ketoconazole), Metopirone (metyrapone), and Lysodren (mitotane).

What are the market dynamics of Cushing’s syndrome?

The launch of three new treatments across the forecast period – Recorlev, Relacorilant, and SPI-62 will drive an increase in the overall market size of CS as more efficacious therapeutic options to become available to patients. The increasing access of patients in the EU, specifically Germany, to the novel steroidogenesis inhibitor Isturisa will drive the growth of the CS market and erode the market share of more traditional, less effective therapies such as ketoconazole and Metyrapone.

The lack of late-stage pipeline products for CS represents an opportunity for companies to help develop transformational therapies to expand treatment options by developing trials with meaningful primary endpoints beyond plasma cortisol reduction, which is often used for therapies in development. A need remains for efficacious therapies that target the underlying cause of CD. There is steadily increasing awareness among physicians regarding CS symptomatology as novel therapies enter the market.

What are the major drugs for Cushing’s syndrome?

Signifor/Signifor LAR, Korlym, Isturisa, Metopirone, Lysodren, and Ketoconazole (branded and generic) are the major drugs in Cushing’s syndrome market.

Market report scope

Market size (Year – 2020) $121.4 million
Growth rate CAGR of >10% from 2021 to 2030
Base year for estimation 2020
Forecast period 2021-2030
Key Drugs Signifor/Signifor LAR, Korlym, Isturisa, Metopirone, Lysodren, and Ketoconazole (branded and generic).
Key Therapies Steroidogenesis Inhibitor, GR-II Antagonist, and SPI-62.
Companies covered Corcept Therapeutics Inc., Recordati SpA, Laboratorie HRA Pharma SAS, Strongbridge Biopharma PLC., and Sparrow Pharmaceuticals.

GlobalData’s “Cushing’s Syndrome – Opportunity Assessment and Forecast to 2030” combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the CS market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CS market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of the various competitor.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

Corcept Therapeutics Inc.
Recordati SpA
Laboratorie HRA Pharma SAS
Strongbridge Biopharma PLC.
Sparrow Pharmaceuticals

Table of Contents

1 Executive Summary

1.1 Executive Summary

2 Disease Overview

2.1 Overview of Cushing’s Syndrome

2.2 Cushing’s Syndrome SWOT Analysis

2.3 Classification of Cushing’s Syndrome

3 Epidemiology

3.1 Diagnosed Prevalent Cases of CS, 2020-2030

3.2 Diagnosed Prevalent Cases of CS by Specific Type, 2020

3.3 Sources and Methodology

3.4 Diagnosis of Cushing’s Syndrome – Treatable Population

4 Current Treatment Options

4.1 Treatment Paradigm

4.2 Marketed Products

4.3 Product Profile: Corcept Therapeutics’ Korlym (mifepristone)

4.4 Product Profile: Recordati SpA’s Isturisa (osilodrostat phosphate)

4.5 Product Profile: Recordatii SpAs Signifor (pasireotide)

4.6 Product Profile: Laboratorie HRA Pharma SAS’ Ketoconazole

4.7 Product Profile: Laboratorie HRA Pharma SAS’ Metopirone (metyrapone)

4.8 Product Profile: Laboratorie HRA Pharma SAS’ Lysodren (mitotane)

5 Unmet Needs and Opportunities

5.1 Unmet Needs in CS

5.2 Efficacious Therapies that Target Underlying Causes of CD

5.3 Therapies for Severe CS with Improved Efficacy and Safety

5.4 Physician Awareness of CS Symptomatology

5.5 Improved Referral Systems to Specialists in Secondary Healthcare Settings

5.6 Defined Guidelines for Treatment and Remission

6 Pipeline Assessment

6.1 Cushing’s Syndrome Pipeline Overview

6.2 Leading Pipeline Agents

6.3 Product Profile: Recorlev

6.4 Product Profile: Relacorilant

6.5 Product Profile: SPI-62

6.6 Pipeline Products – Review Designations

6.7 Cushing’s Syndrome: Clinical Trials Overview, Phase II/III

7 R&D Strategies

7.1 Trends in Clinical Trial Design in Cushing’s Syndrome

7.2 Trends in Deal-Making in Cushing’s Syndrome

8 Market Outlook

8.1 Cushing’s Syndrome Sales Forecast

8.2 Cushing’s Syndrome Market Forecast

8.3 Market Drivers and Barriers

9 Appendix

9.1 Primary Research: KOL Information

9.2 About the Authors

10 Contact Us

Figures

Figure 1: Summary of Key Findings

Frequently asked questions

Cushing’s Syndrome – Opportunity Assessment and Forecast to 2030 thematic reports
Currency USD
$6,995

Can be used by individual purchaser only

$20,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Cushing’s Syndrome – Opportunity Assessment and Forecast to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cushing’s Syndrome – Opportunity Assessment and Forecast to 2030 in real time.

  • Access a live Cushing’s Syndrome – Opportunity Assessment and Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.